Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Review Article (Mini-Review)

Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic

Author(s): Suman K. Ray and Sukhes Mukherjee*

Volume 15 , Issue 2 , 2020

Page: [89 - 103] Pages: 15

DOI: 10.2174/1574891X15999200918144833

Price: $65

Abstract

Coronavirus disease is a potentially deadly disease and of significant apprehension for global communal health because of its lethality. Vaccines and antiviral medications are still under trial to prevent or treat human coronavirus (HCoV) till date. The virus HCoV originated in 2003, SARS-CoV, which causes respiratory syndrome having distinctive pathogenesis and infections of the respiratory tract. A mechanism was projected for the evolution of SARS virus, and a handy association with bats was found. When this virus reaches the respective host system, the infection starts with spike protein binding to its complementary receptor of the host cell. The coronavirus spike protein’s association with its host cell receptor complement is crucial in deciding the virus infectivity, tissue tropism and species variety. Recent studies show that SARS Coronavirus 2 or COVID-19 requires protease to get into cells, offering a new therapeutic target. Distinctive attention and exertions should be given to defending or reducing transmission in vulnerable populaces, including those directly associated with caregiving and treatment and also aged one. Researchers are planning to develop a vaccine for COVID-19, and in this approach are also considered developing a vaccine that sensitizes our immune system preventing from this pandemic. The present review focuses on the role of S-spike protein in COVID-19, which helps the virus intruding the enzyme ACE2 (Angiotensin-Converting Enzyme 2). Passive antibody therapy is an additional alternative to use blood donors from hale and hearty people who have already recovered from COVID-19 and therapeutic advancement in handling the COVID-19 pandemic.

Keywords: COVID-19, transmission, health care, angiotensin-converting enzyme 2, pandemic, antiviral medications.

Graphical Abstract
[1]
Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[2]
Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012; 86(7): 3995-4008.
[http://dx.doi.org/10.1128/JVI.06540-11] [PMID: 22278237]
[3]
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020; 7(1): 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 31928528]
[4]
Richman DD, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. ASM Press: Washington 2016.
[http://dx.doi.org/10.1128/9781555819439]
[5]
Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8(Suppl.): S9-S14.
[http://dx.doi.org/10.1046/j.1440-1843.2003.00518.x] [PMID: 15018127]
[6]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing: Treasure Island, FL 2020.
[7]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367(6485): 1444-8.
[http://dx.doi.org/10.1126/science.abb2762] [PMID: 32132184]
[8]
Wang LS, Wang Y, Ye D, Liu Q. A review of the Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents 2020; 55(6): 105948.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105948] [PMID: 32201353]
[9]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new Coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[10]
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16(1): 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[11]
Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol 2014; 88(10): 5209-12.
[http://dx.doi.org/10.1128/JVI.03488-13] [PMID: 24600003]
[12]
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6(3): 315-31.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[13]
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[14]
Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med 2009; 30(1): 67-85.
[http://dx.doi.org/10.1055/s-0028-1119811] [PMID: 19199189]
[15]
Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH. The SARS coronavirus nucleocapsid protein--forms and functions. Antiviral Res 2014; 103: 39-50.
[http://dx.doi.org/10.1016/j.antiviral.2013.12.009] [PMID: 24418573]
[16]
Lau SK, Woo PC, Yip CC, Tse H, Tsoi HW, Cheng VC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 2006; 44(6): 2063-71.
[http://dx.doi.org/10.1128/JCM.02614-05] [PMID: 16757599]
[17]
Abdul-Rasool S, Fielding BC. Understanding human coronavirus HCoV-NL63. Open Virol J 2010; 4: 76-84.
[http://dx.doi.org/10.2174/1874357901004010076] [PMID: 20700397]
[18]
Mohd HA, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir. Virol J 2016; 13: 87.
[http://dx.doi.org/10.1186/s12985-016-0544-0] [PMID: 27255185]
[19]
Wertheim JO, Chu DK, Peiris JS, Kosakovsky Pond SL, Poon LL. A case for the ancient origin of coronaviruses. J Virol 2013; 87(12): 7039-45.
[http://dx.doi.org/10.1128/JVI.03273-12] [PMID: 23596293]
[20]
Gouilh MA, Puechmaille SJ, Gonzalez JP, Teeling E, Kittayapong P, Manuguerra JC. SARS-Coronavirus ancestor’s foot-prints in South-East Asian bat colonies and the refuge theory. Infect Genet Evol 2011; 11(7): 1690-702.
[http://dx.doi.org/10.1016/j.meegid.2011.06.021] [PMID: 21763784]
[21]
Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y. Evolutionary insights into the ecology of coronaviruses. J Virol 2007; 81(8): 4012-20.
[http://dx.doi.org/10.1128/JVI.02605-06] [PMID: 17267506]
[22]
Official Updates Coronavirus, latest COVID-19 news world. Available at: https://www.worldometers.info/coronavirus/
[23]
Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens 2020; 9(3): 231.
[http://dx.doi.org/10.3390/pathogens9030231] [PMID: 32245083]
[24]
Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW, et al. Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis 2004; 10(2): 320-6.
[http://dx.doi.org/10.3201/eid1002.030913] [PMID: 15030705]
[25]
Fehr AR, Perlman S. Coronaviruses: An Overview Of Their Replication And Pathogenesis.Coronaviruses. New York: Humana Press 2015; pp. 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1]
[26]
Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997; 48: 1-100.
[http://dx.doi.org/10.1016/S0065-3527(08)60286-9] [PMID: 9233431]
[27]
Remais J. Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China. Adv Exp Med Biol 2010; 673: 79-98.
[http://dx.doi.org/10.1007/978-1-4419-6064-1_6] [PMID: 20632531]
[28]
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012; 4(6): 1011-33.
[http://dx.doi.org/10.3390/v4061011] [PMID: 22816037]
[29]
Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 2005; 79(23): 14614-21.
[http://dx.doi.org/10.1128/JVI.79.23.14614-14621.2005] [PMID: 16282461]
[30]
Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person- to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020; 395(10230): 1137-44.
[31]
Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382: 1708-20.
[32]
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[33]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[34]
World health Organization news Available at: www.who.int/csr/don/05-january-2020.
[35]
Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323(16): 1545-6.
[http://dx.doi.org/10.1001/jama.2020.4031] [PMID: 32167538]
[36]
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323(18): 1775-6.
[http://dx.doi.org/10.1001/jama.2020.4683] [PMID: 32203977]
[37]
Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. Lancet 2020; 395(10229): 1035-6.
[http://dx.doi.org/10.1016/S0140-6736(20)30668-1] [PMID: 32199073]
[38]
KDCA. Updates on COVID-19 in Korea 2020. Available at: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030 (Accessed on: March 14, 2020).
[39]
39. World Health Organization. Novel coronavirus situation report-2 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200122-sitrep-2-2019-ncov.pdf (Accessed on: January 23, 2020).
[40]
Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020; 221(11): 1757-61.
[http://dx.doi.org/10.1093/infdis/jiaa077]
[41]
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9]
[42]
42. Centers for Disease Control and Prevention. Strategies to Prevent the Spread of COVID-19 in Long-Term Care Facilities (LTCF). Available at: https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/prevent-spread-in-long-term-care-facilities.html (Accessed on: March 08, 2020).
[43]
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China. Euro Surveill 2020; 25(5): 2000062.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.2000062] [PMID: 32046819]
[44]
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172(9): 577-82.
[http://dx.doi.org/10.7326/M20-0504] [PMID: 32150748]
[45]
Chan PK, Tang JW, Hui DS. SARS: clinical presentation, transmission, pathogenesis and treatment options. Clin Sci (Lond) 2006; 110(2): 193-204.
[http://dx.doi.org/10.1042/CS20050188] [PMID: 16411895]
[46]
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv 2020; Available at: https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1.article-info
[47]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585]
[48]
Li Z, Wu M, Guo J, Yao J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of 2019-nCoV Patients. medRxiv 2020; Available at: https://www.medrxiv.org/content/10.1101/2020.02.08.20021212v2.
[49]
Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect 2020; 81(1): e33-9.
[http://dx.doi.org/10.1016/j.jinf.2020.04.004] [PMID: 32294504]
[50]
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[51]
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[52]
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[53]
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020; 323(16): 1612-4.
[http://dx.doi.org/10.1001/jama.2020.4326] [PMID: 32191259]
[54]
Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71(15): 748-55.
[55]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality article-titleoration UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[56]
Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ 2015; 187(4): 257-64.
[http://dx.doi.org/10.1503/cmaj.130375] [PMID: 25667260]
[57]
Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv 2020; Available at: https://www.medrxiv.org/content/10.1101/2020.02.10.20021832v1
[58]
58. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection 2019. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. (Accessed on: February 14, 2020).
[59]
Wong HY, Lam HY, Fong AH, Leung ST, Chin TW, Lo CS, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 2019; 296(2): E72-8.
[http://dx.doi.org/10.1148/radiol.2020201160] [PMID: 32216717]
[60]
60. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. Available at: https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection. (Accessed on: April 01, 2020).
[61]
Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiolology 2020; 2(3.)
[62]
Zhao W, Zhong Z, Xie X, Yu Q, Liu J. relation between chest ct findings and clinical conditions of Coronavirus Disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol 2020; 214(5): 1072-7.
[http://dx.doi.org/10.2214/AJR.20.22976] [PMID: 32125873]
[63]
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR testing for Coronavirus Disease 2019 (COVID-19) in China: A report of 1014 Cases. Radiology 2020; 296(2): E32-40.
[http://dx.doi.org/10.1148/radiol.2020200642] [PMID: 32101510]
[64]
Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TM, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020; 296(2): E46-54.
[http://dx.doi.org/10.1148/radiol.2020200823] [PMID: 32155105]
[65]
Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020; 296(2): E41-5.
[http://dx.doi.org/10.1148/radiol.2020200343]
[66]
Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. Novel Coronavirus pneumonia (COVID-19) progression course in 17 discharged patients: comparison of clinical and thin-section CT features during recovery. Clin Infect Dis 2020; 71(15): 723-31.
[http://dx.doi.org/10.1093/cid/ciaa271]
[67]
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21(3): 335-7.
[http://dx.doi.org/10.1016/S1470-2045(20)30096-6] [PMID: 32066541]
[68]
Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association between renin-angiotensin system blockade discontinuation and all- cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 2020; 180(5): 718-26.
[http://dx.doi.org/10.1001/jamainternmed.2020.0193] [PMID: 32150237]
[69]
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract 2020; 162: 108142.
[http://dx.doi.org/10.1016/j.diabres.2020.108142] [PMID: 32278764]
[70]
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019. Morb Mortal Wkly Rep 2020; 69(13): 382-6.
[71]
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS CoV2 patients of novel coronavirus disease 2019. Clic Inf dis 2020; 71(16): 2027-34.
[72]
Tobaigy M, Qashqary S, Al-Dahery A, Mujallad A, Hershan MA, Kamal N. Therapeutic management of patients with COVID-19: a systematic review. Infect Prev in Pract 2020; 2(3): 100061.
[http://dx.doi.org/10.1016/j.infpip.2020.100061]
[73]
McCreary EK, Pogue JM. Coronavirus Disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 2020; 7(4): ofaa105.
[http://dx.doi.org/10.1093/ofid/ofaa105] [PMID: 32284951]
[74]
74. Gilead. Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV). Available at: https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus. (Accessed on: February 02, 2020).
[75]
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396): 9.
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID: 28659436]
[76]
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[77]
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[78]
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020; 20(6): 697-706.
[http://dx.doi.org/10.1016/S1473-3099(20)30200-0] [PMID: 32224310]
[79]
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295(15): 4773-9.
[80]
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531(7594): 381-5.
[http://dx.doi.org/10.1038/nature17180] [PMID: 26934220]
[81]
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[82]
82. US Food and Drug Administration. Available at: https://www.fda.gov/media/136534/download. (Accessed on: March 30, 2020).
[83]
Simpson TF, Kovacs RJ, Steckler EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular. (Accessed on: March 30, 2020).
[84]
84. Centers for Disease Control and Prevention. Therapeutic options for patients with COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. (Accessed on March 22, 2020).
[85]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[86]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4): 105932.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[87]
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279-83.
[http://dx.doi.org/10.1016/j.jcrc.2020.03.005] [PMID: 32173110]
[88]
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychlroquine in patients with COVID-19: results of a randomized clinical trial Available at: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3. (Accessed on: April 01, 2020)
[89]
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949.
[90]
Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50(4): 384.
[http://dx.doi.org/10.1016/j.medmal.2020.03.006] [PMID: 32240719]
[91]
Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ 2020; 49(2): 215-9.
[92]
Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5(3): 147-55.
[http://dx.doi.org/10.1016/S1473-3099(05)70022-0] [PMID: 15766649]
[93]
Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12): 1904-13.
[http://dx.doi.org/10.1093/infdis/jiv392] [PMID: 26198719]
[94]
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[95]
Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci USA 2008; 105(42): 16119-24.
[http://dx.doi.org/10.1073/pnas.0805240105] [PMID: 18852458]
[96]
96. National Health Commission (NHC) of the People’s Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 2020. Available at: http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm. (Accessed on: 6 March 2020).
[97]
Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323(15): 1488-94.
[http://dx.doi.org/10.1001/jama.2020.3204] [PMID: 32125362]
[98]
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. HKU/UCH SARS Study Group Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252-6.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[99]
Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 2016; 9(3): 227-30.
[http://dx.doi.org/10.1016/j.jiph.2016.04.001] [PMID: 27095301]
[100]
Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, et al. US Nitazoxanide Influenza Clinical Study Group Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014; 14(7): 609-18.
[http://dx.doi.org/10.1016/S1473-3099(14)70717-0] [PMID: 24852376]
[101]
Gamiño-Arroyo AE, Guerrero ML, McCarthy S, Ramírez-Venegas A, Llamosas-Gallardo B, Galindo-Fraga A, et al. Mexico Emerging Infectious Diseases Clinical Research Network (LaRed). Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis 2019; 69(11): 1903-11.
[http://dx.doi.org/10.1093/cid/ciz100] [PMID: 30753384]
[102]
Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 2019; 15(8): 813-22.
[http://dx.doi.org/10.1080/1744666X.2019.1629904] [PMID: 31219357]
[103]
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25(4): 625-38.
[http://dx.doi.org/10.1016/j.bbmt.2018.12.758] [PMID: 30592986]
[104]
Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis 2018; 67(4): 533-40.
[http://dx.doi.org/10.1093/cid/ciy152] [PMID: 29481659]
[105]
Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018; 23(8): 943-7.
[http://dx.doi.org/10.1634/theoncologist.2018-0028] [PMID: 29622697]
[106]
Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289(21): 2801-9.
[http://dx.doi.org/10.1001/jama.289.21.JOC30885] [PMID: 12734147]
[107]
Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348(20): 1986-94.
[http://dx.doi.org/10.1056/NEJMoa030685] [PMID: 12682352]
[108]
Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004; 10(4): 581-6.
[http://dx.doi.org/10.3201/eid1004.030458] [PMID: 15200845]
[109]
Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis 2019; 70(9): 1837-44.
[http://dx.doi.org/10.1093/cid/ciz544] [PMID: 31925415]
[110]
Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290(24): 3222-8.
[http://dx.doi.org/10.1001/jama.290.24.3222] [PMID: 14693875]
[111]
Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health 2018; 11(1): 9-17.
[http://dx.doi.org/10.1016/j.jiph.2017.08.009] [PMID: 28864360]
[112]
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. Convalescent Plasma Study Group The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211(1): 80-90.
[http://dx.doi.org/10.1093/infdis/jiu396] [PMID: 25030060]
[113]
Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10(7): 676-8.
[http://dx.doi.org/10.1111/j.1469-0691.2004.00956.x] [PMID: 15214887]
[114]
Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4): 447-56.
[http://dx.doi.org/10.1093/cid/ciq106] [PMID: 21248066]
[115]
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24(1): 44-6.
[http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID: 15616839]
[116]
Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA 2016; 315(20): 2190-9.
[http://dx.doi.org/10.1001/jama.2016.5828] [PMID: 27209269]
[117]
Lim CC, Tan CS, Kaushik M, Tan HK. Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study. Nephrology (Carlton) 2015; 20(3): 148-54.
[http://dx.doi.org/10.1111/nep.12364] [PMID: 25395245]
[118]
Di L, Fu Y, Sun Y, Li J, Liu L, Yao J, et al. RNA sequencing by direct tagmentation of RNA/DNA hybrids. Proc Natl Acad Sci USA 2020; 117(6): 2886-93.
[119]
World Health Organization. Novel Coronavirus 2019. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management. (Accessed on: February 02, 2020).
[120]
World Health Organization. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts 2020. Available at: https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts. (Accessed on: February 14, 2020).
[121]
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). J UpToDate 2020.
[123]
How COVID-19 Spreads CDCgov US Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/index.html. (Accessed on: 25 February 2020).
[124]
World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected 2020. Available at: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. (Accessed on: February 04, 2020).
[125]
Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) or Patients Under Investigation for 2019-nCoV in Healthcare Settings 2019. Available at: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html. (Accessed on: March 19, 2020).
[126]
Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104(3): 246-51.
[http://dx.doi.org/10.1016/j.jhin.2020.01.022] [PMID: 32035997]
[127]
Mandl JN, Ahmed R, Barreiro LB, Daszak P, Epstein JH, Virgin HW, et al. Reservoir host immune responses to emerging zoonotic viruses. Cell 2015; 160(1-2): 20-35.
[http://dx.doi.org/10.1016/j.cell.2014.12.003] [PMID: 25533784]
[128]
Robledo D, Taggart JB, Ireland JH, McAndrew BJ, Starkey WG, Haley CS, et al. Gene expression comparison of resistant and susceptible Atlantic salmon fry challenged with Infectious Pancreatic Necrosis virus reveals a marked contrast in immune response. BMC Genomics 2016; 17(1): 279.
[http://dx.doi.org/10.1186/s12864-016-2600-y] [PMID: 27066778]
[129]
Thaker SK, Ch’ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol 2019; 17(1): 59.
[http://dx.doi.org/10.1186/s12915-019-0678-9] [PMID: 31319842]
[130]
Hughes JM, Wilson ME, Pike BL, Saylors KE, Fair JN, LeBreton M, et al. The origin and prevention of pandemics. Clin Infect Dis 2010; 50(12): 1636-40.
[http://dx.doi.org/10.1086/652860] [PMID: 20450416]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy